Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review

IF 7 Q1 HEALTH CARE SCIENCES & SERVICES Lancet Regional Health-Americas Pub Date : 2024-10-01 DOI:10.1016/j.lana.2024.100899
Nikki Bozinoff , Erin Grennell , Charlene Soobiah , Zahraa Farhan , Terri Rodak , Christine Bucago , Katie Kingston , Michelle Klaiman , Brittany Poynter , Dominick Shelton , Elizabeth Schoenfeld , Csilla Kalocsai
{"title":"Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review","authors":"Nikki Bozinoff ,&nbsp;Erin Grennell ,&nbsp;Charlene Soobiah ,&nbsp;Zahraa Farhan ,&nbsp;Terri Rodak ,&nbsp;Christine Bucago ,&nbsp;Katie Kingston ,&nbsp;Michelle Klaiman ,&nbsp;Brittany Poynter ,&nbsp;Dominick Shelton ,&nbsp;Elizabeth Schoenfeld ,&nbsp;Csilla Kalocsai","doi":"10.1016/j.lana.2024.100899","DOIUrl":null,"url":null,"abstract":"<div><div>Buprenorphine initiation in the Emergency Department (ED) has been hailed as an evidence-based strategy to mitigate the opioid overdose crisis, but its implementation has been limited. This scoping review synthesizes barriers and facilitators to buprenorphine initiation in the ED, and uses the Consolidated Framework for Implementation Research and a critical lens to analyze the literature. Results demonstrate an immense effort across the U.S. and Canada to implement ED-initiated buprenorphine. Facilitators include multidisciplinary addiction teams and co-located, low-barrier, harm reduction-informed services to support transitions. Barriers include a failure to address structural stigma, client complexity, and an increasingly toxic drug supply. The literature also misses the opportunity to include the perspectives of service users, health administrators, and learners. Increased coordination of implementation efforts, and a shift to equitable and inclusive opioid agonist therapy initiation pathways are needed across the U.S. and Canada.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"38 ","pages":"Article 100899"},"PeriodicalIF":7.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Regional Health-Americas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667193X24002266","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Buprenorphine initiation in the Emergency Department (ED) has been hailed as an evidence-based strategy to mitigate the opioid overdose crisis, but its implementation has been limited. This scoping review synthesizes barriers and facilitators to buprenorphine initiation in the ED, and uses the Consolidated Framework for Implementation Research and a critical lens to analyze the literature. Results demonstrate an immense effort across the U.S. and Canada to implement ED-initiated buprenorphine. Facilitators include multidisciplinary addiction teams and co-located, low-barrier, harm reduction-informed services to support transitions. Barriers include a failure to address structural stigma, client complexity, and an increasingly toxic drug supply. The literature also misses the opportunity to include the perspectives of service users, health administrators, and learners. Increased coordination of implementation efforts, and a shift to equitable and inclusive opioid agonist therapy initiation pathways are needed across the U.S. and Canada.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
急诊科开始使用丁丙诺啡的促进因素和障碍:范围界定审查
在急诊科(ED)启动丁丙诺啡治疗被誉为缓解阿片类药物过量危机的循证策略,但其实施却十分有限。这篇范围综述综述了在急诊科启动丁丙诺啡的障碍和促进因素,并使用实施研究综合框架和批判性视角对文献进行了分析。研究结果表明,美国和加拿大在实施急诊室启动丁丙诺啡方面做出了巨大努力。促进因素包括多学科戒毒团队和同地、低障碍、减低伤害的服务,以支持过渡。障碍包括未能解决结构性污名化、客户复杂性以及日益有毒的药物供应。文献中也没有纳入服务使用者、健康管理者和学习者的观点。美国和加拿大需要加强对实施工作的协调,并转向公平、包容的阿片类激动剂治疗启动途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.00
自引率
0.00%
发文量
0
期刊介绍: The Lancet Regional Health – Americas, an open-access journal, contributes to The Lancet's global initiative by focusing on health-care quality and access in the Americas. It aims to advance clinical practice and health policy in the region, promoting better health outcomes. The journal publishes high-quality original research advocating change or shedding light on clinical practice and health policy. It welcomes submissions on various regional health topics, including infectious diseases, non-communicable diseases, child and adolescent health, maternal and reproductive health, emergency care, health policy, and health equity.
期刊最新文献
Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study Antimicrobial utilisation patterns between 2013 and 2022 in Canadian neonates born at less than 33 weeks gestation: a retrospective cohort study Candidate drug repurposing for malaria: perspectives for optimising clinical trials Overlap and predominance of cancer over cardiovascular deaths: insights about the epidemiological transition in Brazil Increased risks of mosquito-borne disease emergence in temperate regions of South America
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1